Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Distinctive behavioral and cellular responses to fluoxetine in the mouse model for Fragile X syndrome.

Uutela M, Lindholm J, Rantamäki T, Umemori J, Hunter K, Võikar V, Castrén ML.

Front Cell Neurosci. 2014 May 28;8:150. doi: 10.3389/fncel.2014.00150. eCollection 2014 May 28.

2.

BDNF and TrkB in neuronal differentiation of Fmr1-knockout mouse.

Louhivuori V, Vicario A, Uutela M, Rantamäki T, Louhivuori LM, Castrén E, Tongiorgi E, Akerman KE, Castrén ML.

Neurobiol Dis. 2011 Feb;41(2):469-80. doi: 10.1016/j.nbd.2010.10.018. Epub 2010 Nov 1.

PMID:
21047554
3.

Reduction of BDNF expression in Fmr1 knockout mice worsens cognitive deficits but improves hyperactivity and sensorimotor deficits.

Uutela M, Lindholm J, Louhivuori V, Wei H, Louhivuori LM, Pertovaara A, Akerman K, Castrén E, Castrén ML.

Genes Brain Behav. 2012 Jul;11(5):513-23. doi: 10.1111/j.1601-183X.2012.00784.x. Epub 2012 Apr 11.

4.

Exaggerated behavioral phenotypes in Fmr1/Fxr2 double knockout mice reveal a functional genetic interaction between Fragile X-related proteins.

Spencer CM, Serysheva E, Yuva-Paylor LA, Oostra BA, Nelson DL, Paylor R.

Hum Mol Genet. 2006 Jun 15;15(12):1984-94. Epub 2006 May 4.

PMID:
16675531
5.

Anxiety, hyperactivity and stereotypy in a zebrafish model of fragile X syndrome and autism spectrum disorder.

Kim L, He L, Maaswinkel H, Zhu L, Sirotkin H, Weng W.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Dec 3;55:40-9. doi: 10.1016/j.pnpbp.2014.03.007. Epub 2014 Mar 27.

PMID:
24681195
6.

Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome.

Lovelace JW, Wen TH, Reinhard S, Hsu MS, Sidhu H, Ethell IM, Binder DK, Razak KA.

Neurobiol Dis. 2016 May;89:126-35. doi: 10.1016/j.nbd.2016.02.002. Epub 2016 Feb 2.

PMID:
26850918
7.

BDNF in fragile X syndrome.

Castrén ML, Castrén E.

Neuropharmacology. 2014 Jan;76 Pt C:729-36. doi: 10.1016/j.neuropharm.2013.05.018. Epub 2013 May 29. Review.

PMID:
23727436
8.

Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome.

Spencer CM, Alekseyenko O, Serysheva E, Yuva-Paylor LA, Paylor R.

Genes Brain Behav. 2005 Oct;4(7):420-30.

9.

Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome.

Thomas AM, Bui N, Graham D, Perkins JR, Yuva-Paylor LA, Paylor R.

Behav Brain Res. 2011 Oct 1;223(2):310-21. doi: 10.1016/j.bbr.2011.04.049. Epub 2011 May 6.

10.

Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice.

Dansie LE, Phommahaxay K, Okusanya AG, Uwadia J, Huang M, Rotschafer SE, Razak KA, Ethell DW, Ethell IM.

Neuroscience. 2013 Aug 29;246:186-98. doi: 10.1016/j.neuroscience.2013.04.058. Epub 2013 May 7.

11.

Modeling fragile X syndrome in the Fmr1 knockout mouse.

Kazdoba TM, Leach PT, Silverman JL, Crawley JN.

Intractable Rare Dis Res. 2014 Nov;3(4):118-33. doi: 10.5582/irdr.2014.01024. Review.

12.

Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome.

Costa L, Spatuzza M, D'Antoni S, Bonaccorso CM, Trovato C, Musumeci SA, Leopoldo M, Lacivita E, Catania MV, Ciranna L.

Biol Psychiatry. 2012 Dec 1;72(11):924-33. doi: 10.1016/j.biopsych.2012.06.008. Epub 2012 Jul 18.

PMID:
22817866
13.

Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice.

Deltheil T, Guiard BP, Cerdan J, David DJ, Tanaka KF, Repérant C, Guilloux JP, Coudoré F, Hen R, Gardier AM.

Neuropharmacology. 2008 Nov;55(6):1006-14. doi: 10.1016/j.neuropharm.2008.08.001. Epub 2008 Aug 12. Review.

PMID:
18761360
14.

Dietary supplementation of omega-3 fatty acids rescues fragile X phenotypes in Fmr1-Ko mice.

Pietropaolo S, Goubran MG, Joffre C, Aubert A, Lemaire-Mayo V, Crusio WE, Layé S.

Psychoneuroendocrinology. 2014 Nov;49:119-29. doi: 10.1016/j.psyneuen.2014.07.002. Epub 2014 Jul 9.

PMID:
25080404
15.

Hyperactivity and lack of social discrimination in the adolescent Fmr1 knockout mouse.

Sørensen EM, Bertelsen F, Weikop P, Skovborg MM, Banke T, Drasbek KR, Scheel-Krüger J.

Behav Pharmacol. 2015 Dec;26(8 Spec No):733-40. doi: 10.1097/FBP.0000000000000152.

PMID:
26110222
16.

Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice.

Michalon A, Bruns A, Risterucci C, Honer M, Ballard TM, Ozmen L, Jaeschke G, Wettstein JG, von Kienlin M, Künnecke B, Lindemann L.

Biol Psychiatry. 2014 Feb 1;75(3):189-97. doi: 10.1016/j.biopsych.2013.05.038. Epub 2013 Jul 30.

PMID:
23910948
17.

Selective Deletion of Astroglial FMRP Dysregulates Glutamate Transporter GLT1 and Contributes to Fragile X Syndrome Phenotypes In Vivo.

Higashimori H, Schin CS, Chiang MS, Morel L, Shoneye TA, Nelson DL, Yang Y.

J Neurosci. 2016 Jul 6;36(27):7079-94. doi: 10.1523/JNEUROSCI.1069-16.2016.

18.

Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome.

Thomas AM, Bui N, Perkins JR, Yuva-Paylor LA, Paylor R.

Psychopharmacology (Berl). 2012 Jan;219(1):47-58. doi: 10.1007/s00213-011-2375-4. Epub 2011 Jun 10.

PMID:
21656124
19.

Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model.

Goebel-Goody SM, Wilson-Wallis ED, Royston S, Tagliatela SM, Naegele JR, Lombroso PJ.

Genes Brain Behav. 2012 Jul;11(5):586-600. doi: 10.1111/j.1601-183X.2012.00781.x. Epub 2012 Apr 6.

20.

Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model.

Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM.

J Med Genet. 2009 Feb;46(2):94-102. doi: 10.1136/jmg.2008.061796. Epub 2008 Oct 3.

PMID:
18835858

Supplemental Content

Support Center